Efficacy, Safety, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Study of Ravulizumab in Chinese Adult Patients with NMOSD

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 25c2c92109dedb3b244940eb5e945ba926541ad3
First added on: Sep 12, 2026